Metastatic Hepatocellular Carcinoma Withdrawn Phase 1 / 2 Trials for Pegargiminase (DB06592)

Also known as: Hepatocellular Carcinoma Metastatic / Metastatic hepatocellular carcinoma (disorder) / Metastatic hepatocellular carcinoma (morphologic abnormality) / Liver cell carcinoma / Primary liver cell carcinoma (disorder) / Hepatocellular carcinoma / Carcinoma hepatocellular / Hepatoma / Primary carcinoma of liver (disorder) / Liver carcinoma / Carcinoma liver / Liver cell carcinoma (disorder) / Hepatocellular carcinoma (morphologic abnormality) / Carcinoma of liver / Carcinoma, Hepatocellular

IndicationStatusPhase
DBCOND0041971 (Metastatic Hepatocellular Carcinoma)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06006286A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaTreatment